Enoxaparin Use in the Neonatal Intensive Care Unit: Experience Over 8 Years
| Autor: | Anthony K.C. Chan, David S. C. Lee, Dion Pepelassis, Janet I. Malowany, David C. Knoppert |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Neonatal intensive care unit Dose medicine.drug_class Injections Subcutaneous Low molecular weight heparin Hemorrhage law.invention Catheters Indwelling law Intensive Care Units Neonatal medicine Humans Enoxaparin Adverse effect Retrospective Studies Dose-Response Relationship Drug business.industry Anticoagulant Infant Newborn Anticoagulants Thrombosis Retrospective cohort study General Medicine Intensive care unit Bone Diseases Metabolic Anesthesia Factor Xa Female business Enoxaparin sodium Infant Premature medicine.drug |
| Zdroj: | Pharmacotherapy. 27:1263-1271 |
| ISSN: | 0277-0008 |
| Popis: | Study Objective. To evaluate the effectiveness and safety of enoxaparin therapy in a neonatal intensive care unit (NICU). Design. Retrospective chart review. Setting. Level III NICU in a Canadian academic center. Patients. All neonates treated with enoxaparin while in the NICU between January 1, 1998, and June 1, 2006. Measurements and Main Results. Data abstracted included patient demographics, diagnosis of thrombosis and its progression, enoxaparin dosages with corresponding antifactor Xa levels, and adverse events. Sixteen neonates (four term, 12 preterm) were treated with enoxaparin at a mean ± SD initial subcutaneous dose of 1.41 ± 0.15 mg/kg every 12 hours. The target therapeutic range (antifactor Xa level 0.5-1.0 U/ml) was achieved by 12 infants at a mean ± SD dose of 1.92 ± 0.43 mg/kg every 12 hours, after a mean of 5.6 days (range 1–15 days). Preterm infants required a higher dose (per kilogram) compared with term infants to maintain therapeutic antifactor Xa levels (mean ± SD 1.94 ± 0.39 vs 1.65 ± 0.14 mg/kg every 12 hrs, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text